Bausch + Lomb Corporation (BLCO) on Monday reported positive 24-month results from a pivotal study of the ELIOS System, an implant-free procedure for treating elevated intraocular pressure (IOP) in patients with open-angle glaucoma. The company's shares were up more than 5% in pre-market trading.
The study enrolled patients on glaucoma medications who had been diagnosed with mild to moderate primary open-angle glaucoma and cataracts. It evaluated two co-primary endpoints: the proportion of patients achieving at least a 20% reduction in IOP and the mean reduction in IOP.
The ELIOS system met both co-primary effectiveness endpoints, demonstrating statistically significant and clinically meaningful reductions in IOP.
Key findings included a 20% or greater reduction in unmedicated diurnal IOP in 76% of patients and an average decrease of 7.4 mmHg. Additionally, 82% of patients were medication-free at 23 months.
No intraoperative complications were reported during the ELIOS procedure, and postoperative adverse event rates were comparable to cataract surgery alone.
The company said ELIOS has been available in Europe for several years and remains under development in the United States.
Bausch + Lomb shares had closed at $15.72 on Friday, down 2.78%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.